Plain-English translation of NCT06332885 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing the Zephyr Endobronchial Valve, a small device placed inside the lungs during a minimally invasive procedure to help people with severe emphysema breathe better. The valve blocks off the most damaged part of the lung, allowing healthier lung tissue to work more effectively. Researchers are tracking how safe and effective this treatment is in Japanese patients over one year.
Severe emphysema causes the lungs to become dangerously over-inflated, making it very hard to breathe and limiting what patients can do. This treatment offers a less invasive option than surgery to help reduce that over-inflation and improve lung function.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll have a special breathing tube procedure (bronchoscopy) where doctors confirm the valve will work for you, then place the device in your most damaged lung area. You'll stay in the hospital for at least 3 nights for monitoring, then follow a breathing exercise program for 8 weeks. Over the next 12 months, you'll return for check-ups at 3, 6, and 12 months, including breathing tests, walking tests, CT scans, and questionnaires about how you're feeling.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Japan